î
îŒ
ãã°ã€ã³
î
AbbVie Inc
ABBV207.111USD
+2.181+1.06%
çµå€Â 03/25, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
327.37Bæ䟡ç·é¡
87.52çŽè¿12ã¶æPER
î
詳现æ å ± AbbVie Inc äŒæ¥å
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
AbbVie Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãABBV
äŒç€ŸåAbbVie Inc
äžå Žæ¥Jan 02, 2013
æé«çµå¶è²¬ä»»è
ãCEOãMichael (Robert A)
åŸæ¥å¡æ°55000
蚌åžçš®é¡Ordinary Share
決ç®ææ«Jan 02
æ¬ç€Ÿæåšå°1 N Waukegan Rd
éœåžNORTH CHICAGO
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœUnited States of America
éµäŸ¿çªå·60064
é»è©±çªå·18479327900
ãŠã§ããµã€ãhttps://www.abbvie.com/
äŒæ¥ã³ãŒãABBV
äžå Žæ¥Jan 02, 2013
æé«çµå¶è²¬ä»»è
ãCEOãMichael (Robert A)
AbbVie Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.27K
+10.04%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.89%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
52.38K
+19.28%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.80%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.13%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.37%
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
28.96K
+4.15%
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
16.50K
+7.29%
Mr. Timothy J. Richmond
Mr. Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
6.13K
-346.66%
Ms. Jennifer L. Davis
Ms. Jennifer L. Davis
Independent Director
Independent Director
2.52K
+47.64%
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.27K
+10.04%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.89%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
52.38K
+19.28%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.80%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.13%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.37%
åçå èš³
é貚: USDæŽæ°æå»: Tue, Jan 6
é貚: USDæŽæ°æå»: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Immunology-SKYRIZI
4.71B
29.84%
Immunology-RINVOQ
2.18B
13.84%
Immunology-HUMIRA
993.00M
6.29%
Neuroscience-Botox Therapeutic
985.00M
6.24%
Neuroscience-Vraylar
934.00M
5.92%
ä»ã®
5.97B
37.85%
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
United States
11.53B
73.07%
International
3.35B
21.21%
All other countries
660.00M
4.18%
Collaboration revenue
243.00M
1.54%
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Immunology-SKYRIZI
4.71B
29.84%
Immunology-RINVOQ
2.18B
13.84%
Immunology-HUMIRA
993.00M
6.29%
Neuroscience-Botox Therapeutic
985.00M
6.24%
Neuroscience-Vraylar
934.00M
5.92%
ä»ã®
5.97B
37.85%
æ ªäž»
æŽæ°æå»: Thu, Feb 12
æŽæ°æå»: Thu, Feb 12
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
The Vanguard Group, Inc.
10.18%
BlackRock Institutional Trust Company, N.A.
5.38%
State Street Investment Management (US)
4.58%
Geode Capital Management, L.L.C.
2.52%
JP Morgan Asset Management
1.97%
ä»ã®
75.38%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
The Vanguard Group, Inc.
10.18%
BlackRock Institutional Trust Company, N.A.
5.38%
State Street Investment Management (US)
4.58%
Geode Capital Management, L.L.C.
2.52%
JP Morgan Asset Management
1.97%
ä»ã®
75.38%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor
44.71%
Investment Advisor/Hedge Fund
21.14%
Research Firm
3.07%
Pension Fund
2.32%
Bank and Trust
2.30%
Sovereign Wealth Fund
1.54%
Insurance Company
0.67%
Hedge Fund
0.46%
Family Office
0.22%
ä»ã®
23.57%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Mon, Dec 8
æŽæ°æå»: Mon, Dec 8
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
5311
1.33B
74.86%
+1.37M
2025Q3
5386
1.32B
74.95%
+8.86M
2025Q2
5326
1.32B
74.78%
+2.41M
2025Q1
5334
1.32B
74.15%
+3.84M
2024Q4
5267
1.31B
73.92%
+9.35M
2024Q3
4970
1.30B
74.13%
-1.24M
2024Q2
4907
1.30B
73.33%
+14.47M
2024Q1
4916
1.28B
72.48%
+1.37M
2023Q4
4861
1.27B
72.12%
+10.24M
2023Q3
4666
1.27B
72.28%
+8.75M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
The Vanguard Group, Inc.
176.93M
10.01%
+427.57K
+0.24%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
92.78M
5.25%
+679.67K
+0.74%
Sep 30, 2025
State Street Investment Management (US)
79.82M
4.52%
-202.47K
-0.25%
Sep 30, 2025
Geode Capital Management, L.L.C.
40.44M
2.29%
+1.26M
+3.22%
Sep 30, 2025
JP Morgan Asset Management
36.42M
2.06%
-1.05M
-2.81%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
23.10M
1.31%
-1.99M
-7.94%
Jun 30, 2025
Capital Research Global Investors
25.23M
1.43%
-34.75K
-0.14%
Sep 30, 2025
Charles Schwab Investment Management, Inc.
25.96M
1.47%
-825.22K
-3.08%
Sep 30, 2025
Fidelity Management & Research Company LLC
19.95M
1.13%
+301.27K
+1.53%
Sep 30, 2025
Morgan Stanley Smith Barney LLC
23.97M
1.36%
+460.64K
+1.96%
Sep 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
VanEck Pharmaceutical ETF
9.64%
First Trust NASDAQ Pharmaceuticals ETF
8.05%
Health Care Select Sector SPDR Fund
7.89%
Proshares Ultra Health Care
7.62%
iShares U.S. Healthcare ETF
7.57%
JPMorgan Healthcare Leaders ETF
6.87%
Simplify Health Care ETF
6.73%
Fidelity MSCI Health Care Index ETF
6.5%
Harbor Health Care ETF
6.18%
iShares Core High Dividend ETF
5.9%
詳现ãèŠã
VanEck Pharmaceutical ETF
æ¯ç9.64%
First Trust NASDAQ Pharmaceuticals ETF
æ¯ç8.05%
Health Care Select Sector SPDR Fund
æ¯ç7.89%
Proshares Ultra Health Care
æ¯ç7.62%
iShares U.S. Healthcare ETF
æ¯ç7.57%
JPMorgan Healthcare Leaders ETF
æ¯ç6.87%
Simplify Health Care ETF
æ¯ç6.73%
Fidelity MSCI Health Care Index ETF
æ¯ç6.5%
Harbor Health Care ETF
æ¯ç6.18%
iShares Core High Dividend ETF
æ¯ç5.9%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
40.87B
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
Feb 19, 2026
ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on May 15, 2026 going ex on Apr 15, 2026 with reinvestment option
Apr 15, 2026
May 15, 2026
Apr 15, 2026
Oct 31, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on Feb 17, 2026 going ex on Jan 16, 2026 with reinvestment option
Jan 16, 2026
Feb 17, 2026
Jan 16, 2026
Sep 05, 2025
ABBV.NB Final Cash Dividend of gross USD 1.64 paid on Nov 14, 2025 going ex on Oct 15, 2025 with reinvestment option
Oct 15, 2025
Nov 14, 2025
Oct 15, 2025
Jun 20, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option
Jul 15, 2025
Aug 15, 2025
Jul 15, 2025
Feb 13, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option
Apr 15, 2025
May 15, 2025
Apr 15, 2025
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 06, 2024
ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 21, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 15, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option
Apr 15, 2024
May 15, 2024
Apr 12, 2024
詳现ãèŠã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
ããŒã¿ãªã
